- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Veradermics, Inc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Do | Veradermics, Inc - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering | 54 | Business Wire | NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated ("Veradermics"), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics... ► Artikel lesen | |
| Do | A cut above: Veradermics locks in $256M IPO and shares spike | 1 | FiercePharma | ||
| Do | Eikon, Veradermics close IPOs, as Salspera joins queue | 1 | pharmaphorum | ||
| Mi | Soaring Veradermics IPO Shows Investor Interest In Hair-Loss Companies Isn't Thinning | 1 | Crunchbase News | ||
| Mi | Baldness Biotech Veradermics Prices $256M IPO for Pivotal Tests of Pill for Hair Loss | 1 | MedCity News | ||
| VERADERMICS Aktie jetzt für 0€ handeln | |||||
| Mi | Veradermics-Aktie steigt bei NYSE-Debüt um 118 % nach erweitertem Börsengang | 2 | Investing.com Deutsch | ||
| Mi | Veradermics surges on public debut after upsized offering | 1 | Seeking Alpha | ||
| Mi | Hair loss biotech Veradermics prices upsized IPO at $17, above the range | 1 | Renaissance Capital | ||
| Mi | Hair loss pill developer Veradermics raises $256.3M in upsized IPO | 2 | Seeking Alpha | ||
| Mi | Veradermics Prices IPO At $17 Per Share | 570 | AFX News | WASHINGTON (dpa-AFX) - Veradermics, Incorporated (MANE), a late clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 15.08 million shares... ► Artikel lesen | |
| Mi | Veradermics prices upsized IPO at $17 per share, raises $256.3 million | 2 | Investing.com | ||
| Mi | Veradermics Announces Pricing of Upsized Initial Public Offering | 328 | Business Wire | NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated ("Veradermics"), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics... ► Artikel lesen | |
| Di | Veradermics, Inc - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 29.01. | Hair loss pill developer Veradermics seeks up to $534M valuation in U.S. IPO | 5 | Seeking Alpha | ||
| 28.01. | Hair loss biotech Veradermics sets terms for $200 million IPO | 1 | Renaissance Capital | ||
| 28.01. | Veradermics, Inc - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 10.01. | Hair loss biotech Veradermics files for a $100 million IPO | 4 | Renaissance Capital | ||
| 09.01. | Veradermics, Inc - S-1, General form for registration of securities | - | SEC Filings |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 72,82 | 0,00 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 73,21 | 0,00 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| RECURSION PHARMACEUTICALS | 3,565 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 305,95 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 16,550 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 | - Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEVE... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 75,82 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| ERASCA | 11,885 | 0,00 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| LIMINATUS PHARMA | 2,030 | 0,00 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| ARCELLX | 66,94 | 0,00 % | Arcellx reports D-Domain binder shows no tonic signaling in CAR T therapy | ||
| SUMMIT THERAPEUTICS | 13,860 | 0,00 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ALUMIS | 26,340 | 0,00 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| IMMUNOVANT | 24,060 | -4,33 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| CG ONCOLOGY | 49,210 | 0,00 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,720 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,740 | 0,00 % | Beam Therapeutics Inc. - 8-K, Current Report |
VERADERMICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 36,250 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VERADERMICS INC finden Sie auf Wallstreet Online.